Sepsis is a very serious and potentially life-threatening condition caused by the body’s response to severe infection. It is most common in the very young and elderly.
Studies indicate that aspirin may help reduce the severity of inflammation associated with infection and may subsequently reduce the severity of sepsis. However, this has not been proven.
The ASPREE ANTI-SEPSIS (AspiriN To Inhibit SEPSIS) sub-study will determine whether low dose aspirin:
- reduces the number of severe infection episodes requiring hospital admissions
- reduces ICU (Intensive Care Unit) admissions among patients hospitalised for severe sepsis
- reduces the mortality rate of sepsis in older people
What does participation involve?
This study collects information entirely through medical records. If a participant has been hospitalised for an infection, we will contact the hospital to collect details of the infection.
Results will be collated in 2018 comparing whether daily low dose aspirin helps prevent or reduce severe infection or if it makes no difference. It will also be another factor to consider in the overall benefits versus the risks of daily 100mg aspirin in older people.
How to find out more about ASPREE ANTI-SEPSIS:
- Ring 1800 728 745 (toll free from a landline)
Collaborators:
- Monash University
- The Victorian Infectious Diseases Service
- Melbourne Health
- Alfred Health
- GP Co-investigators
Funding:
- National Health and Medical Research Council